MGTX vs. JSPR, CRBU, TNYA, SOPH, AURA, AVXL, BDTX, IVVD, SLDB, and OCGN
Should you be buying MeiraGTx stock or one of its competitors? The main competitors of MeiraGTx include Jasper Therapeutics (JSPR), Caribou Biosciences (CRBU), Tenaya Therapeutics (TNYA), SOPHiA GENETICS (SOPH), Aura Biosciences (AURA), Anavex Life Sciences (AVXL), Black Diamond Therapeutics (BDTX), Invivyd (IVVD), Solid Biosciences (SLDB), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry.
MeiraGTx (NASDAQ:MGTX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.
MeiraGTx currently has a consensus target price of $26.00, indicating a potential upside of 405.84%. Jasper Therapeutics has a consensus target price of $64.29, indicating a potential upside of 209.66%. Given MeiraGTx's higher probable upside, analysts plainly believe MeiraGTx is more favorable than Jasper Therapeutics.
MeiraGTx received 162 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Jasper Therapeutics an outperform vote while only 71.10% of users gave MeiraGTx an outperform vote.
Jasper Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -651.19%. Jasper Therapeutics' return on equity of -63.21% beat MeiraGTx's return on equity.
67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 9.7% of MeiraGTx shares are held by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Jasper Therapeutics had 4 more articles in the media than MeiraGTx. MarketBeat recorded 12 mentions for Jasper Therapeutics and 8 mentions for MeiraGTx. Jasper Therapeutics' average media sentiment score of 0.79 beat MeiraGTx's score of -0.39 indicating that Jasper Therapeutics is being referred to more favorably in the news media.
MeiraGTx has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500.
Jasper Therapeutics has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Jasper Therapeutics beats MeiraGTx on 10 of the 16 factors compared between the two stocks.
Get MeiraGTx News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MeiraGTx Competitors List
Related Companies and Tools
